Skip to main content

Teva Pharmaceutical Value Stock - Dividend - Research Selection

Teva Pharmaceutical

ISIN: US8816242098, WKN: 883035

Market price date: 08.01.2021
Market price: 10,79 USD




Teva Pharmaceutical Fundamental data and company key figures of the share

Annual reports in USD
Key figures 23-02-2020
Cash flow
Net operating cash flow 748.000.000
Capital Expenditures -525.000.000
Free cash flow 223.000.000
Balance sheet
Total Equity 13.972.000.000
Liabilities & Shareholders equity 57.582.000.000
Income statement
Net income -999.000.000
Eps (diluted) -0,916
Diluted shares outstanding 1.090.610.000
Net sales/revenue 16.887.000.000

Fundamental ratios calculated on: 08-01-2021

Ratios
Key figures 08-01-2021
Cash flow
P/C 0,00
   
P/FC 0,00
Balance sheet
ROI-1,74
ROE24,27
Income statement
P/E-11,78
Div. Yield0,00%
P/B0,00
P/S0,70


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolTEVA
Market Capitalization11.767.682.048,00 USD
CountryIsrael
IndicesNO INDEX
SectorsPharma
Raw Data SourceUS GAAP in Millionen USD
Stock Split2004-07-02,2.0000/1.0000; 2004-07-01,2.0000/1.0000; 2002-12-07,2.0000/1.0000; 2002-12-06,2.0000/1.0000; 2000-02-24,2.0000/1.0000; 2000-02-23,2.0000/1.0000; 2000-02-22,1.0000/1.0000; 1993-04-15,2.0000/1.0000; 1993-04-14,2.0000/1.0000; 1982-08-16,1.000000/1.000000
Internetwww.tevapharm.com


Description of the company

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment\'s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.tevapharm.com